Mechanisms of Metabolic and Hormone Action on Plaque Formation in Brain and Carotid Vessels in Patients With Prostate Adenocarcinoma
2020年12月8日 更新者:University of Washington
Mechanisms of Metabolic and Hormone Action on Plaque Formation in Brain and Carotid Vessels in Men Undergoing Androgen Deprivation Therapy
This trial studies the mechanisms of metabolic and hormone action on plaque formation in brain and carotid vessels in patients with prostate adenocarcinoma.
Studying the biomarkers in the laboratory may help doctors know the impact of androgen deprivation on metabolic, brain and cardiovascular endpoints.
調査の概要
詳細な説明
OUTLINE:
Patients undergo clinical evaluations over 12 months including physical exam and vital signs, waist to hip circumference, medical history and events, laboratory evaluations, imaging evaluations, cognitive function evaluations, gait assessment, and quality of life questionnaires.
研究の種類
観察的
入学 (実際)
2
連絡先と場所
このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。
研究場所
-
-
Washington
-
Seattle、Washington、アメリカ、98109
- Fred Hutch/University of Washington
-
-
参加基準
研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。
適格基準
就学可能な年齢
- 子
- 大人
- 高齢者
健康ボランティアの受け入れ
いいえ
受講資格のある性別
男
サンプリング方法
非確率サンプル
調査対象母集団
Participants with prostate adenocarcinoma
説明
Inclusion Criteria:
- Signed informed consent
- Histologically confirmed adenocarcinoma of the prostate
- Non-castrate disease with a serum testosterone level >= 50 ng/dL (1.73 nmol/L) at baseline
- No evidence of distant metastatic disease on baseline computed tomography-chest, abdomen and pelvis (CT-CAP) and bone scans
Patients will be stratified by the presence or absence of pre-existing cardiovascular disease defined as at least one of the following:
- Prior myocardial infarction >= 30 days before enrollment
Prior revascularization procedure >= 30 days before consent, including:
- Coronary artery stent placement or balloon angioplasty
- Coronary artery bypass graft surgery
- Stent placement or balloon angioplasty to a carotid, iliac, femoral, or popliteal artery
- Carotid endarterectomy surgery
- Vascular bypass surgery of the iliac, femoral, or popliteal artery
- Results from angiogram or CT angiogram of coronary, carotic, iliac, femoral, or popliteal arteries that documents at least one vascular stenosis >= 50% at any time point before enrollment
- Carotid ultrasound results that shows stenosis >= 50% at any time point before enrollment
- Ankle-brachial pressure index < 0.9 at any time point before enrollment
- Intent to initiate continuous androgen deprivation therapy (ADT) for at least 12 months
Exclusion Criteria:
- No prior treatment with ADT at time of study entry. (Prior neoadjuvant/adjuvant ADT is allowed only if the last injection of a depot formulation wore off at least 12 months prior to enrollment)
- Previous or concurrent hormonal or systemic therapy for prostate cancer including: anti-androgens, estrogens, megestrol acetate, ketoconazole, abiraterone, enzalutamide, or chemotherapy. (Prior or planned neoadjuvant bicalutamide for prevention of tumor flare is allowed)
- Plans to start or continue treatment with an investigational product after enrollment
- Poorly controlled type 1 or type 2 diabetes mellitus, based on hemoglobin A1c, as judged by the investigator
- Prior or planned surgical castration
- Poorly controlled hypertension at time of study entry, as judged by the investigator
- Myocardial infarction or stroke < 30 days prior to enrollment
- Coronary, carotid, or peripheral artery revascularization < 30 days prior to enrollment
- Planned or scheduled cardiac surgery or percutaneous coronary intervention (PCI) procedure that is known at the time of enrollment
- Mental incapacity or language barrier precluding adequate understanding or cooperation
- Inability to tolerate magnetic resonance imaging (MRI) imaging, or both Lupron and Degarelix
- Any other clinically significant disorder which may affect the subject's health or the outcome of the trial as judged by the investigator
- Estimated glomerular filtration rate (eGFR) < 45
- History of allergy to gadolinium contrast agent
研究計画
このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。
研究はどのように設計されていますか?
デザインの詳細
コホートと介入
グループ/コホート |
介入・治療 |
|---|---|
|
Clinical Evaluations
Patients undergo clinical evaluations over 12 months including physical exam and vital signs, waist to hip circumference, medical history and events, laboratory evaluations, imaging evaluations, cognitive function evaluations, gait assessment, and quality of life questionnaires.
|
補助研究
Undergo clinical evaluations
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in visual characterization of 18F-florbetapir (Amyvid) positron emission tomography (PET) scans results after Andorgen Deprivation Therapy
時間枠:12 Months
|
Change From Baseline visual characterization scan results at 12 months
|
12 Months
|
|
Change standardized uptake values of 18F-florbetapir (Amyvid) positron emission tomography (PET) scans results
時間枠:12 Months
|
Change from baseline standardized uptake values in select regions of interest at 12 months
|
12 Months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Cognitive test results: Story recall
時間枠:12 months
|
Change in baseline Story Recall results at 12 months
|
12 months
|
|
Cognitive Test Results: Change in Montreal Cognitive Assessment (MOCA)
時間枠:12 Months
|
Change in baseline MOCA score results at 12 months
|
12 Months
|
|
Cognitive Test Results: Change in Clinical Dementia Rating Scale
時間枠:12 Months
|
Change in baseline Clinical Dementia Rating Scale score at 12 months
|
12 Months
|
|
Cognitive Test Results: Digit span
時間枠:12 Months
|
Change in baseline Digit span results at 12 months
|
12 Months
|
|
Cognitive Test Results: Letter number sequencing
時間枠:12 Months
|
Change in baseline Letter number sequencing results at 12 months
|
12 Months
|
|
Cognitive Test Results: Stroop Test Results
時間枠:12 Months
|
Change in baseline Stroop Test Results at 12 months
|
12 Months
|
|
Cognitive Test Results: Symbol Digit Modalities Test
時間枠:12 Months
|
Change in baseline Symbol Digit Modalities Test score at 12 months
|
12 Months
|
|
Cognitive Test Results: Visuo-Spatial Learning Test
時間枠:12 Months
|
Change in baseline Visuo-Spatial Learning Test results at 12 months
|
12 Months
|
|
Cognitive Test Results: Rey auditory verbal learning test (RVLT)
時間枠:12 Months
|
Change in baseline Rey auditory verbal learning test (RVLT) score at 12 months
|
12 Months
|
|
Inflammatory and immune markers: Change in CRP
時間枠:12 Months
|
Change in baseline CRP values at 12 months
|
12 Months
|
|
Inflammatory and immune markers: Change in IGFBP3
時間枠:12 Months
|
Change in baseline IGFBP3 at 12 months
|
12 Months
|
|
Inflammatory and immune markers: Change in IGFBP1
時間枠:12 Months
|
Change in baseline IGFBP1 at 12 months
|
12 Months
|
|
Inflammatory and immune markers: Change in IGF-1
時間枠:12 Months
|
Change in baseline IGF-1 at 12 months
|
12 Months
|
|
Inflammatory and immune markers: Change in IL-6
時間枠:12 Months
|
Change in baseline IL-6 at 12 months
|
12 Months
|
|
Metabolic Markers: Change in HgbA1C
時間枠:12 Months
|
Change in baseline HgbA1C at 12 months
|
12 Months
|
|
Metabolic Markers: Change in Estradiol
時間枠:12 Months
|
Change in baseline Estradiol at 12 months
|
12 Months
|
|
Metabolic Markers: Change in Follicle Stimulating Hormone (FSH)
時間枠:12 Months
|
Change in baseline Change in Follicle Stimulating Hormone (FSH) at 12 months
|
12 Months
|
|
Metabolic Markers: Change in Leptin
時間枠:12 Months
|
Change in baseline Leptin at 12 months
|
12 Months
|
|
Metabolic Markers: Change in Adiponectin
時間枠:12 Months
|
Change in baseline Adiponectin at 12 months
|
12 Months
|
|
Metabolic Markers: Change in homeostatic model assessment of insulin resistance (HOMA-IR)
時間枠:12 Months
|
Change in baseline HOMA-IR values at 12 months; Calculated based on fasting glucose and insulin test results.
|
12 Months
|
協力者と研究者
ここでは、この調査に関係する人々や組織を見つけることができます。
スポンサー
捜査官
- 主任研究者:Evan Yu、Fred Hutch/University of Washington Cancer Consortium
研究記録日
これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。
主要日程の研究
研究開始 (実際)
2019年10月8日
一次修了 (実際)
2020年3月12日
研究の完了 (実際)
2020年3月12日
試験登録日
最初に提出
2018年9月12日
QC基準を満たした最初の提出物
2018年10月22日
最初の投稿 (実際)
2018年10月24日
学習記録の更新
投稿された最後の更新 (実際)
2020年12月10日
QC基準を満たした最後の更新が送信されました
2020年12月8日
最終確認日
2020年12月1日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。